Related Experiment Videos
[Cyclophosphamide haemorragic cystitis in a child. Radiological and endoscopic aspects (author's transl)]
Insights
Hemorrhagic cystitis is a known complication of cyclophosphamide therapy. This case highlights bladder wall irregularities and edema in a child, emphasizing the need for further management strategies.
Area of Science:
- Urology
- Pediatric Oncology
- Oncology
Background:
- Cyclophosphamide is a widely used chemotherapeutic agent.
- Hemorrhagic cystitis is a recognized adverse effect of cyclophosphamide treatment.
- Early identification and management are crucial for patient outcomes.
Observation:
- A 7-year-old boy undergoing lymphosarcoma treatment presented with bladder wall irregularities on excretory urogram.
- Cystoscopy revealed significant bullous edema and hyperemia of the bladder.
- Biopsy confirmed normal urothelium with underlying edema and congestion, ruling out malignancy.
Findings:
- The patient exhibited symptoms consistent with hemorrhagic cystitis secondary to cyclophosphamide.
- Diagnostic imaging and cystoscopy were key in assessing the bladder's condition.
- Histopathological examination was essential to exclude tumor recurrence.
Implications:
- This case underscores the importance of monitoring for hemorrhagic cystitis in patients receiving cyclophosphamide.
- Prompt diagnosis and appropriate management are vital to prevent complications.
- Further research into endoscopic and surgical interventions for persistent hematuria is warranted.
Abstract:
Haemorragic cystitis is a well known complication of cyclophosphamide therapy. In the reported case, a 7 years old boy treated for lymphosarcoma, as an excretory urogram demonstrated important focal irregularity of the bladder wall. Cystoscopy revealed areas of important bullous oedema with generalized hyperemia. A biopsy disclosed normal urothelium raised by oedematous and congestive chorion and excluded a malignant tumor. Various kinds of endoscopic and surgical procedures are reported to control persisting hematuria after withdrawal of the cyclophosphamide treatment.